Introduction: A Medical Breakthrough 150 Years in the Making
A team of Japanese scientists has achieved a medical milestone: the creation of a bacterial cancer therapy that works without the immune system. This groundbreaking approach could redefine how we fight cancer, especially for patients weakened by chemotherapy or immunodeficiency.
Developed by Professor Eijiro Miyako and his team at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and the University of Tsukuba, this new treatment — known as AUN therapy — uses two types of bacteria that work in perfect harmony to destroy tumors safely and effectively.
The Long Journey: From 19th-Century Discoveries to Modern Innovation
The idea of treating cancer with bacteria is not new. In 1868, German physician Busch documented a patient whose tumor regressed after a bacterial infection. Later, in 1893, Dr. William Coley developed bacterial-based cancer injections — the early ancestors of today’s immunotherapies like CAR-T cell therapy and checkpoint inhibitors.
While those methods revolutionized oncology, they all share one major weakness: they rely on the immune system’s strength. For patients with weakened immunity, these treatments often fail to deliver lasting results.
That challenge inspired Professor Miyako’s team to find a new solution — one that works even when the immune system does not.
AUN Therapy: Two Bacteria, One Powerful Alliance
At the core of this innovation lies a unique microbial partnership called AUN, named after the Japanese concept symbolizing balance and harmony between opposites.
AUN therapy combines two natural bacterial species that complement each other perfectly:
- Proteus mirabilis (A-gyo): A bacterium that naturally infiltrates tumors, attacking cancer cells and disrupting blood supply.
- Rhodopseudomonas palustris (UN-gyo): A photosynthetic bacterium that supports and regulates A-gyo’s behavior.
Together, they create a self-regulating system capable of targeting and destroying tumors without external immune assistance.
How AUN Works: Smart Bacteria That Outsmart Cancer
The AUN bacterial consortium is a living, intelligent system that adapts within the tumor environment. Here’s how it works:
- Precise Tumor Targeting:
AUN bacteria locate and infiltrate tumor blood vessels, cutting off oxygen and nutrients. - Structural Transformation:
Once inside, A-gyo changes shape (filamentation) in response to tumor-specific chemicals, boosting its tumor-killing ability. - Dynamic Bacterial Ratio:
The bacterial balance naturally shifts from 3:97 (A-gyo to UN-gyo) to around 99:1, maximizing its cancer-fighting potential. - Reduced Side Effects:
AUN’s built-in balance prevents overgrowth and minimizes cytokine release syndrome (CRS) — a dangerous immune reaction common in traditional therapies.
This biological precision makes AUN both effective and remarkably safe.
The Harmony of AUN: Balancing Power and Safety
The beauty of AUN lies in its symbiotic equilibrium.
While A-gyo aggressively attacks tumors, UN-gyo moderates its behavior, ensuring stability and safety within the body. This collaboration reflects the ancient Japanese concept of “AUN” — the peaceful coexistence of opposing forces.
This harmony allows the bacteria to remain compatible with human tissue, showing minimal toxicity and strong biocompatibility in both animal and early human models.
Next Steps: Toward Human Clinical Trials
Professor Miyako’s team is preparing to launch a startup to accelerate the clinical development of AUN therapy.
“A new chapter in bacteria-based cancer therapy — pursued for over 150 years — is finally beginning,” said Professor Eijiro Miyako.
Clinical trials are expected to begin within six years, potentially opening the door to immune-independent cancer treatments for millions of patients worldwide.
A New Hope for Immune-Weakened Cancer Patients
For patients whose immune systems are damaged or suppressed, AUN represents something unprecedented: a safe, self-regulating bacterial therapy that fights cancer on its own.
By merging synthetic biology, microbial intelligence, and oncology, AUN therapy may soon mark the beginning of a new era — one where the smallest organisms on Earth help conquer one of humanity’s biggest challenges.
Conclusion: The Dawn of Immune-Free Cancer Therapy
After 150 years of scientific pursuit, the dream of an immune-independent bacterial cancer therapy has finally become reality.
The AUN system developed by Professor Miyako and his collaborators stands as a symbol of innovation, harmony, and hope — offering a path toward cancer treatments that are safer, smarter, and universally effective.a turning point for cancer patients with weakened immune systems. It offers a long-sought option where conventional immunotherapies fall short, signaling the arrival of truly immune-independent cancer treatment.
